Methamphetamine-like discriminative-stimulus effects of nicotinic agonists

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 3, 2014, Pages 478-488

  Desai, Rajeev I ^a   Bergman, Jack ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABASEINE; ANABASINE; CYTISINE; DIHYDRO BETA ERYTHROIDINE; EPIBATIDINE; ISOARECOLONE; LOBELINE; METHAMPHETAMINE; NICOTINE; NICOTINIC AGENT; UNCLASSIFIED DRUG; VARENICLINE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CONVULSION; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DISCRIMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; HYPERSALIVATION; MALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RECEPTOR BINDING; SQUIRREL MONKEY; TREMOR; VOMITING;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DISCRIMINATION (PSYCHOLOGY); DOPAMINE AGENTS; DRUG PARTIAL AGONISM; MALE; METHAMPHETAMINE; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; SAIMIRI;

EID: 84896707937     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.211235     Document Type: Article

References (56)

1. Anderson DJ and Arneric SP (1994) Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain. Eur J Pharmacol 253: 261-267.
2. Arendash GW, Sengstock GJ, Sanberg PR, and Kem WR (1995) Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 674:252-259.
3. Badio B and Daly JW (1994) Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol 45:563-569.
4. Benowitz NL (2010) Nicotine addiction. N Engl J Med 362:2295-2303.
5. Brioni JD, Kim DJ, O'Neill AB, Williams JE, and Decker MW (1994) Clozapine attenuates the discriminative stimulus properties of (-)-nicotine. Brain Res 643:1-9.
6. Brioni JD, Kim DJ, and O'Neill AB (1996) Nicotine cue: lack of effect of the alpha 7 nicotinic receptor antagonist methyllycaconitine. Eur J Pharmacol 301:1-5.
7. Clemens KJ, Caillé S, Stinus L, and Cador M (2009) The addition of five minor tobacco alkaloids increases nicotine-induced hyperactivity, sensitization and intravenous self-administration in rats. Int J Neuropsychopharmacol 12:1355-1366.
8. Cunningham CS, Polston JE, Jany JR, Segert IL, and Miller DK (2006) Interaction of lobeline and nicotinic receptor ligands with the discriminative stimulus properties of cocaine and amphetamine. Drug Alcohol Depend 84:211-222.
9. Cunningham CS, Javors MA, and McMahon LR (2012) Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys. J Pharmacol Exp Ther 341:840-849.
10. Corrigall WA and Coen KM (1989) Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 99:473-478.
11. Damaj MI, Creasy KR, Grove AD, Rosecrans JA, and Martin BR (1994) Pharmacological effects of epibatidine optical enantiomers. Brain Res 664:34-40.
12. Damaj MI, Patrick GS, Creasy KR, and Martin BR (1997) Pharmacology of lobeline, a nicotinic receptor ligand. J Pharmacol Exp Ther 282:410-419.
13. Damaj MI, Glassco W, Dukat M, and Martin BR (1999) Pharmacological characterization of nicotine-induced seizures in mice. J Pharmacol Exp Ther 291:1284-1291.
14. Decker MW, Brioni JD, Bannon AW, and Arneric SP (1995) Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci 56:545-570.
15. Desai RI and Bergman J (2010) Drug discrimination in methamphetamine- trained rats: effects of cholinergic nicotinic compounds. J Pharmacol Exp Ther 335:807-816.
16. Desai RI, Barber DJ, and Terry P (2003) Dopaminergic and cholinergic involvement in the discriminative stimulus effects of nicotine and cocaine in rats. Psychopharmacology (Berl) 167:335-343.
17. de Fiebre CM, Meyer EM, Henry JC, Muraskin SI, Kem WR, and Papke RL (1995) Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes. Mol Pharmacol 47:164-171.
18. Di Chiara G (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393:295-314.
19. Dobelis P, Hutton S, Lu Y, and Collins AC (2003) GABAergic systems modulate nicotinic receptor-mediated seizures in mice. J Pharmacol Exp Ther 306: 1159-1166.
20. Dwoskin LP and Crooks PA (2002) A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol 63:89-98.
21. Finney DJ (1964) Statistical Method in Biological Assay, Ed. 2nd. Hafner, New York.
22. Fudala PJ and Iwamoto ET (1986) Further studies on nicotine-induced conditioned place preference in the rat. Pharmacol Biochem Behav 25:1041-1049.
23. Hahn B, Sharples CG, Wonnacott S, Shoaib M, and Stolerman IP (2003) Attentional effects of nicotinic agonists in rats. Neuropharmacology 44:1054-1067.
24. Harrod SB, Dwoskin LP, Green TA, Gehrke BJ, and Bardo MT (2003) Lobeline does not serve as a reinforcer in rats. Psychopharmacology (Berl) 165:397-404.
25. Hoffman AC and Evans SE (2013) Abuse potential of non-nicotinic tobacco smoke components: acetaldehyde, nornicotine, cotinine, and anabasine. Nicotine Tob Res 15:622-632.
26. Jensen AA, Mikkelsen I, Frølund B, Bräuner-Osborne H, Falch E, and Krogsgaard-Larsen P (2003) Carbamoylcholine homologs: novel and potent agonists at neuronal nicotinic acetylcholine receptors. Mol Pharmacol 64:865-875.
27. Jutkiewicz EM, Brooks EA, Kynaston AD, Rice KC, and Woods JH (2011) Patterns of nicotinic receptor antagonism: nicotine discrimination studies. J Pharmacol Exp Ther 339:194-202.
28. Kangas BD, Delatte MS, Vemuri VK, Thakur GA, Nikas SP, Subramanian KV, Shukla VG, Makriyannis A, and Bergman J (2013) Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther 344:561-567.
29. Kelleher RT and Morse WH (1968) Determinants of the specificity of behavioral effects of drugs. Ergeb Physiol 60:1-56.
30. Kem WR, Mahnir VM, Papke RL, and Lingle CJ (1997) Anabaseine is a potent agonist on muscle and neuronal alpha-bungarotoxin-sensitive nicotinic receptors. J Pharmacol Exp Ther 283:979-992.
31. LeSage MG, Shelley D, Ross JT, Carroll FI, and Corrigall WA (2009) Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacol Biochem Behav 91:461-467.
32. Marks MJ, Stitzel JA, Romm E, Wehner JM, and Collins AC (1986) Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and alphabungarotoxin. Mol Pharmacol 30:427-436.
33. Marks MJ, Robinson SF, and Collins AC (1996) Nicotinic agonists differ in activation and desensitization of 86Rb1 efflux from mouse thalamic synaptosomes. J Pharmacol Exp Ther 277:1383-1396.
34. Miller DK, Crooks PA, Teng L, Witkin JM, Munzar P, Goldberg SR, Acri JB, and Dwoskin LP (2001) Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J Pharmacol Exp Ther 296:1023-1034.
35. Miller DK, Harrod SB, Green TA, Wong MY, Bardo MT, and Dwoskin LP (2003) Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats. Pharmacol Biochem Behav 74:279-286.
36. Mirza NR, Pei Q, Stolerman IP, and Zetterström TS (1996) The nicotinic receptor agonists (-)-nicotine and isoarecolone differ in their effects on dopamine release in the nucleus accumbens. Eur J Pharmacol 295:207-210.
37. Reavill C, Spivak CE, Stolerman IP, and Waters JA (1987) Isoarecolone can inhibit nicotine binding and produce nicotine-like discriminative stimulus effects in rats. Neuropharmacology 26 (7A):789-792.
38. Reavill C, Jenner P, Kumar R, and Stolerman IP (1988) High affinity binding of [3H] (-)-nicotine to rat brain membranes and its inhibition by analogues of nicotine. Neuropharmacology 27:235-241.
39. Reavill C, Walther B, Stolerman IP, and Testa B (1990) Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology 29: 619-624.
40. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, and Rovetti CC, et al. (2007) Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985-994.
41. Rollema H, Shrikhande A, Ward KM, Tingley FD, 3rd, Coe JW, O'Neill BT, Tseng E, Wang EQ, Mather RJ, and Hurst RS, et al. (2010) Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol 160:334-345.
42. Shoaib M (2006) Effects of isoarecolone, a nicotinic receptor agonist in rodent models of nicotine dependence. Psychopharmacology (Berl) 188:252-257.
43. Smith JW and Stolerman IP (2009) Recognising nicotine: the neurobiological basis of nicotine discrimination. Handb Exp Pharmaco 295-333.
44. Smith JW, Mogg A, Tafi E, Peacey E, Pullar IA, Szekeres P, and Tricklebank M (2007) Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology (Berl) 190:157-170.
45. Snedecor GW and Cochran WG (1967) Statistical Methods, Ed. 6th. Iowa State University Press, Ames, Iowa.
46. Spealman RD (1995) Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 275:53-62.
47. Stevens KE, Kem WR, Mahnir VM, and Freedman R (1998) Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl) 136:320-327.
48. Stolerman IP, Garcha HS, Pratt JA, and Kumar R (1984) Role of training dose in discrimination of nicotine and related compounds by rats. Psychopharmacology (Berl) 84:413-419.
49. Stolerman IP, Garcha HS, and Mirza NR (1995) Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats. Psychopharmacology (Berl) 117:430-437.
50. Stolerman IP, Chandler CJ, Garcha HS, and Newton JM (1997) Selective antagonism of behavioural effects of nicotine by dihydro-beta-erythroidine in rats. Psychopharmacology (Berl) 129:390-397.
51. Sullivan JP, Decker MW, Brioni JD, Donnelly-Roberts D, Anderson DJ, Bannon AW, Kang CH, Adams P, Piattoni-KaplanM, and BuckleyMJ, et al. (1994) (1/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J Pharmacol Exp Ther 271:624-631.
52. Takada K, Swedberg MD, Goldberg SR, and Katz JL (1989) Discriminative stimulus effects of intravenous l-nicotine and nicotine analogs or metabolites in squirrel monkeys. Psychopharmacology (Berl) 99:208-212.
53. Tidey JW and Bergman J (1998) Drug discrimination in methamphetamine- trained monkeys: agonist and antagonist effects of dopaminergic drugs. J Pharmacol Exp Ther 285:1163-1174.
54. Whiteaker P, Garcha HS, Wonnacott S, and Stolerman IP (1995) Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats. Br J Pharmacol 116:2097-2105.
55. Williams M and Robinson JL (1984) Binding of the nicotinic cholinergic antagonist, dihydro-beta-erythroidine, to rat brain tissue. J Neurosci 4:2906-2911.
56. Xiao Y and Kellar KJ (2004) The comparative pharmacology and up-regulation of rat neuronal nicotinic receptor subtype binding sites stably expressed in transfected mammalian cells. J Pharmacol Exp Ther 310:98-107.